Form 4: Citius Pharmaceuticals Director Acquires Stock Options
SEC Form 4
Director Dennis M. McGrath acquired stock options for 125,000 shares of Citius Pharmaceuticals, Inc. on November 7, 2024.
Summary
- Dennis M. McGrath, a director at Citius Pharmaceuticals, Inc., was granted stock options to purchase 125,000 shares of common stock on November 7, 2024.
- These options have an exercise price of $0.38 per share and will vest 100% on the one-year anniversary of the vesting commencement date, provided Mr. McGrath continues to provide service to the company.
- Mr. McGrath also holds previously granted vested stock options for 75,000 shares each at exercise prices of $0.70 and $1.42.
Sentiment
Score: 7
Explanation: The document reflects a standard practice of stock option grants to a director, which is generally viewed positively as it aligns interests with shareholders. There are no negative implications.
Positives
- The grant of stock options to a director aligns their interests with those of the shareholders.
- The vesting schedule encourages continued service and commitment from the director.
Future Outlook
The newly granted options will vest one year from the vesting commencement date, contingent on continued service.
Industry Context
Stock option grants to directors are a common practice in publicly traded companies to incentivize performance and align interests with shareholders.
Comparison to Industry Standards
- Stock option grants are a standard form of compensation for directors in publicly listed companies, such as Citius Pharmaceuticals.
- The vesting period of one year is also a common practice to ensure continued service and commitment from the director.
- The exercise prices of $0.38, $0.70 and $1.42 are specific to Citius Pharmaceuticals and would need to be compared to the current market price of the stock to assess their value.
Stakeholder Impact
- The stock option grant aligns the director's interests with those of the shareholders, potentially leading to better performance and increased shareholder value.
Key Dates
| Date | Description |
|---|---|
| 11/07/2024 | Date of the stock option grant for 125,000 shares. |
| 11/12/2024 | Date of the filing of the Form 4. |
| 10/10/2033 | Expiration date of previously granted stock options with an exercise price of $0.70. |
| 02/07/2033 | Expiration date of previously granted stock options with an exercise price of $1.42. |
| 11/07/2034 | Expiration date of the newly granted stock options with an exercise price of $0.38. |
Keywords
stock options, Citius Pharmaceuticals, director, insider trading, equity, CTXR, vesting
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.